GeoVax Labs Inc News - GOVXW

GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update

Cancer Gene Therapy Program and Next-Generation COVID-19 VaccineAdvancing in Phase 2 Clinical Trials Company...

GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host

ATLANTA, GA, April 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...

GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023

ATLANTA, GA, April 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...

GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate

Analysis of Open-Label Portion of Ongoing Phase 2 Trial of GEO-CM04S1 Presented at 23rd Annual World Vaccine...

GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress

80% Survival in Nonhuman Primates Observed in a Lethal Challenge Model Atlanta, GA, April 05, 2023 (GLOBE...

GeoVax to Participate at the World Vaccine Congress with Multiple Presentations

New data from the ongoing Phase 2 trial of GEO-CM04S1 to be presented Atlanta, GA, March 30, 2023 (GLOBE...

GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update

Company Expands Ongoing Clinical Trials and theBreadth and Capacity of Its Novel Vaccine Platform Technology...

GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress

Dr. Diamond and City of Hope COVID-19 Vaccine Team Nominated forBest Academic/Research Team Award ATLANTA, GA...

GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update

Conference call to be held Thursday, March 23, at 4:30 p.m. Eastern Time ATLANTA, GA, March 09, 2023 (GLOBE...

GeoVax to Participate at the 35th Annual Roth Conference

Company Progress to be Discussed During Analyst-Led Fireside Chat ATLANTA, GA, March 06, 2023 (GLOBE...

GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections

Data Presented Indicated Very High Levels of Immunogenicity of the Combinational Therapy ATLANTA, GA, Feb...

GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial

Mobile Community Clinical Research Facility to be Deployed in California ATLANTA, GA, Feb. 15, 2023 (GLOBE...

GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines

Focused on Providing Rapid Response to Combat Emerging Infectious Threats ATLANTA, GA, Feb. 08, 2023 (GLOBE...

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

Phase 1/2 Trial Now Active at Stanford, Emory, and Thomas Jefferson Universities ATLANTA, GA, Feb. 07, 2023...

GeoVax to Present at the 2023 BIO CEO & Investor Conference

ATLANTA, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

GeoVax Labs Inc (GOVXW)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

GOVXW News

GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update

GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host

GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023

GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate

GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress

GeoVax to Participate at the World Vaccine Congress with Multiple Presentations

GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update

GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress

GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update

GeoVax to Participate at the 35th Annual Roth Conference

GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections

GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial

GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

GeoVax to Present at the 2023 BIO CEO & Investor Conference

GOVXW Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

GeoVax Labs Inc (GOVXW) News

GeoVax Labs Inc (GOVXW)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

GOVXW News

GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update

GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host

GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023

GeoVax Announces Presentation of Preliminary Data from Clinical Trial of Next-Generation COVID-19 Vaccine Candidate

GeoVax Marburg Vaccine Data Presented at the 23rd Annual World Vaccine Congress

GeoVax to Participate at the World Vaccine Congress with Multiple Presentations

GeoVax Reports 2022 Year-End Financial Results and Provides Corporate Update

GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress

GeoVax to Report 2022 Financial Results on Thursday, March 23, 2023 and Provide Corporate Update

GeoVax to Participate at the 35th Annual Roth Conference

GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections

GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial

GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines

GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers

GeoVax to Present at the 2023 BIO CEO & Investor Conference

GOVXW Discussion

Your Recent History